α/β-Hydrolase domain-6-accessible monoacylglycerol controls glucose-stimulated insulin secretion. Glucose-stimulated insulin secretion: a newer perspective. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. Improvement in outcomes of clinical islet transplantation: 1999–2010. Closed-loop systems fare better in maintaining the time spent in target glycaemic range (mean ~71%) than sensor-augumented insulin pumps (mean ~59%).īarton, F.
#Induced pluripotent stem cells review trial#
This report describes results from a multicentre trial evaluating benefits of closed-loop control over sensor-augumented insulin pumps.
Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes.
Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. 369, 362–372 (2013).ĭiabetes Control and Complications Trial Research Group, Nathan, D. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. IDF Atlas 9th edn (IDF, 2019).Īmerican Diabetes Association. Given the remarkable progress in this field, scalable bioengineering processes are also discussed for the realization of the therapeutic potential of derived β-cells. This Review focuses on the current status of generating β-cells via these diverse routes, highlighting the unique advantages and challenges of each approach. Other potential avenues to produce functional β-cells include: transdifferentiation of closely related cell types (for example, other pancreatic islet cells such as α-cells, or other cells derived from endoderm) the engineering of non-β-cells that are capable of modulating blood sugar and the construction of synthetic ‘cells’ or particles mimicking functional aspects of β-cells. Substantial advances have been made in producing mature β-cells from human pluripotent stem cells that respond appropriately to dynamic changes in glucose concentrations in vitro and rapidly function in vivo following transplantation in mice. Generating β-cells to mitigate the aberrant glucose homeostasis manifested in the disease has remained elusive. Please visit the Sponsored Program’s directory to locate your designated representative.Diabetes mellitus, which affects more than 463 million people globally, is caused by the autoimmune ablation or functional loss of insulin-producing β-cells, and prevalence is projected to continue rising over the next decades. For all agreement templates other than the Non-Disclosure Agreement, please work with your designated Proposal & Contract Administrator prior to distributing the template(s) to any collaborators or external entities. The below Agreement templates have been reviewed and approved by Florida Atlantic University’s Office of the General Counsel. Agreements, Forms, and Templates Agreements
0 kommentar(er)
